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Objective: The present study focuses on the prevalence of nutritional depletion in
relation to functional performance, airflow limitation, experienced dyspnoea and
health status in a large multi-center out-patient population with chronic obstructive
pulmonary disease (COPD).
Methods: In 39 out-patient centers in The Netherlands, 389 patients with moderate
to severe COPD (217 men) were recruited. The study evaluated on the baseline
characteristics of the COSMIC study. Measurements included body composition by
bioelectrical impedance analysis, dyspnoea by MRC-score, peripheral muscle
function by isometric handgrip strength and disease-specific health status by
St. George Respiratory Questionnaire.
Results: The prevalence of nutritional depletion (defined as body mass index (BMI)
p21 kg/m2 and/or fat-free mass index (FFMI)p15 (females) orp16 (males) kg/m2)
was high (27%). Prevalence of normal BMI and low FFMI was 15%, and of low BMI and
low FFMI 11%. The prevalence of low BMI as well as low FFMI was significantly higher
in female than in male COPD patients, 18% and 40% vs. 10% and 20%, respectively
(both Po0.01). No differences in FEV1%predicted, dyspnoea score and health status
were observed between depleted and non-depleted COPD patients. Multiple linear
regression analysis in the total group showed that handgrip strength correlated with
FFMI after correction for sex distribution and age, but not FEV1%predicted.Elsevier Ltd. All rights reserved.
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M.A.P. Vermeeren et al.1350Conclusions: The prevalence of nutritional depletion was high in a large out-patient
COPD population in The Netherlands, especially in female COPD patients. Depletion
of FFM was associated with impaired peripheral muscle strength, independent of
disease severity.
& 2005 Elsevier Ltd. All rights reserved.Introduction
Nutritional depletion commonly occurs in patients
with chronic obstructive pulmonary disease
(COPD). Its prevalence is increasing from 20% in
clinically stable out-patients1 up to 35% in patients
eligible for pulmonary rehabilitation.2 Whole body
muscle wasting, and in particular muscle wasting of
the extremities frequently occurs in patients with
COPD.3 Furthermore, depletion of fat-free mass
(FFM) may even occur in normal-weight COPD
patients.2 Loss of FFM, as an indirect measure of
muscle mass, adversely affects respiratory and
peripheral muscle function,1 exercise capacity,2
health status,4 and even mortality rates.5 Thus
nutritional depletion has an important impact on
COPD.
At this moment, most studies concerning the
prevalence of depletion in COPD patients have
been performed in selected populations such as
patients eligible for pulmonary rehabilitation,
hospitalized patients, patients undergoing lung
volume reduction surgery (LVRS) or treated with
long-term oxygen therapy.2,6–11 Only Engelen et al.
have described the prevalence of depletion in an
out-patient population.1 However, this study had a
small sample size and was performed in a single
center.
To our knowledge, no data have been published
on the prevalence of muscle wasting in COPD in a
large out-patient multi-center setting. Further-
more, it is still unclear if nutritional depletion
and thereby reduced muscle function are asso-
ciated with the severity of airflow limitation or
with other factors like gender, age and clinical
symptoms or quality of life.
The present study therefore investigates the
prevalence of nutritional depletion in relation to
functional performance, airflow limitation, dys-
pnoea, and health status in a large out-patient
COPD population. This study was applied on the
baseline characteristics of the COSMIC (COPD
and Seretide: a multi-center intervention and
characterization) study; a double-blind, parallel
group study on the efficacy of the salmeterol/
fluticasone combination product in comparison
with salmeterol alone in patients with moderate
to severe COPD.Methods and materials
Patients
In 39 out-patient centers in The Netherlands,
patients were recruited to participate in the
COSMIC study. Inclusion criteria were:1. Age 40–75 years
2. An established clinical history of COPD
3. Current or ex-smokers with X10 pack years
4. Pre-bronchodilator forced expiratory volume in
1 s (FEV1)%predicted: 30–70%pred
5. Reversibility after inhalation of a b2-agonist
(400 mg salbutamol): o10% FEV1%pred
6. History of at least two COPD exacerbations in
the last year requiring oral corticosteroids and/
or antibiotics.
Patients were excluded if they were suffering
from respiratory diseases other than COPD or other
disorders, if they required regular oxygen therapy
or maintenance systemic corticosteroids or if there
was evidence for alcohol, drug or solvent abuse.
The study was approved by a central medical
ethics committee in The Netherlands and by the
local medical ethics committees of the participat-
ing centers. All subjects gave written informed
consent.
Lung function
FEV1 was calculated from the flow volume curve
measured by spirometry. The highest value from at
least three technically acceptable spirometric
maneuvres was used and the results were expressed
as percentage of reference values.12
Disease severity
Disease severity was defined according to the
currently published GOLD guidelines13 and updated
supplement.14 We divided our patients based on
post-bronchodilator FEV1 into stage 2, moderate
COPD: FEV1 50–80% predicted and with or without
symptoms; and stage 3, severe COPD: FEV1 30–50%
predicted and with or without symptoms. According
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1 and 4 did not participate in the study.
Body weight and body composition
Body height was determined to the nearest 0.5 cm
with subjects standing barefoot. Body weight was
assessed with the beam scale to the nearest 0.1 kg,
with subjects standing barefoot and in light
clothing. Body mass index (BMI) was calculated as
body weight in kg/(height in m)2. Depletion of body
weight was defined as BMIp21 kg/m2.5 Body com-
position was estimated using single-frequency
(50 kHz) bioelectrical impedance analysis (Bodystat
1500, Bodystat Ltd., Douglas, Isle of Man, Britian)
while subjects were in supine position. The
measurements were performed by trained person-
nel. FFM was calculated from COPD- and gender-
specific regression equations.15 FFM depletion was
defined as FFM index (FFMI: FFM in kg/(height in
m)2) p15 (females) or p16 (males) kg/m2.2 Nutri-
tional depletion was defined as BMIp21 kg/m2 and/
or FFMIp15 (females) or p16 (males) kg/m2.
Fat mass (FM) was calculated by subtracting FFM
from body weight. FM index (FMI) was calculated as
FM in kg/(height in m)2. Patients were divided into
four different categories based on BMI and FFMI:
normal BMI and normal FFMI; normal BMI and low
FFMI; low BMI and normal FFMI; low BMI and low
FFMI.2
Peripheral muscle function
Peripheral muscle function was assessed by iso-
metric handgrip strength using a hand-held dynam-
ometer (JAMAR, Preston, Jackson, Michigan, USA).
The isometric grasp was determined by measuring
the maximally developed strength of the flexors of
the right and left hand, respectively. The highest
value of three maneuvres was used. The mean of
the highest value per hand was used in the analysis.
Dyspnoea
Experienced breathlessness was assessed by the
Medical Research Council (MRC). The MRC dyspnoea
scale is a validated and simple questionnaire16 that
consists of five statements: grade 1, ‘‘I only get
breathless with strenuous exercise’’; grade 2,
‘‘I get short of breath when hurrying on the level
or up a slight hill’’; grade 3, ‘‘I walk slower than
people of the same age on the level because of
breathlessness or have to stop for breath when
walking at my own pace on the level’’; grade 4, ‘‘I
stop for breath after walking 100m or after a fewminutes on the level’’; grade 5, ‘‘I am too breath-
less to leave the house’’. The patients selected the
grade that applied to them. MRC-score 3, 4 and 5
were classified as having severe dyspnoea, corre-
sponding with moderate to severe disability.16
Disease-specific health status
Disease-specific health status was measured by the
St. George’s Respiratory Questionnaire (SGRQ),
with the domains: symptoms, activity, impact and
total.17 The SGRQ is a broadly used and well-
validated questionnaire for the assessment of
health status in COPD. A higher score of SGRQ
means greater impairment in health status.
Statistics
To analyze possible associations between the
different parameters, Pearson product moment
correlation coefficients were calculated. When
appropriate, partial correlation coefficients were
calculated to control for the influences of gender
distribution and age. ANOVA was used with age and
sex as covariates to explain the differences
between depleted and non-depleted COPD patients
in handgrip strength and health status. A linear
stepwise regression model was applied on the data
to reveal which variables independently contribu-
ted to the variation in handgrip strength in the
patients.
A P-value of less than 0.05 was considered
statistically significant. Data were expressed as
mean7SD or as median (range) in the text and
tables. The statistical analyses were performed
using the Statistical Product and Service Solutions
(SPSS, version 11.0 for Windows, SPSS Inc., Chicago,
IL, USA).Results
The study group consisted of 389 patients with
COPD (271 men, 70%); Table 1 shows the char-
acteristics of patients with COPD. According to the
GOLD guidelines, the study group represented 214
patients with GOLD stage 2 (55%) and 175 patients
with GOLD stage 3 (45%).
Prevalence of depletion
The prevalence of nutritional depletion (BMI
p21 kg/m2 and/or FFMI p15 (females) or p16
(males) kg/m2) was 27% in the total study popula-
tion. When assessing different types of depletion,
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Figure 1 The prevalence of different depletion cate-
gories stratified by gender. Stripes: normal BM and FFM;
black: normal BM and FFM depletion; white: BM depletion
and normal FFM and dots: depletion of BM and FFM.
Po0:05 between males and females.
Table 1 Characteristics of the total out-patient
COPD population.
N ¼ 389
Male/female 271/118
Mean7SD
Age (years) 6377
FEV1 (%predicted) 51711
Body mass index (kg/m2) 26.174.3
Fat-free mass index (kg/m2) 17.272.2
Fat mass index (kg/m2) 8.872.8
FEV1: forced expiratory volume in 1 s post-bronchodilator.
Table 2 Characteristics of COPD patients strati-
fied by nutritional depletion.
Non-depleted
COPD patients
Depleted
COPD patients
N ¼ 283 N ¼ 106
Male/female 215/68 56/50#
Age (years) 6377 6277
FEV1 (%predicted) 51711 51712
Handgrip strength
(kg)
38711 3179*
Severe dyspnoea
(% of patients)
40 41
N ¼ 273 N ¼ 102
SGRQ—symptoms 57 (11–91) 54 (22–91)
SGRQ—activity 58 (0–100) 59 (11–100)
SGRQ—impact 26 (0–68) 26 (3–73)
SGRQ—total score 40 (1–76) 40 (16–72)
Mean7SD; FEV1: forced expiratory volume in 1 s post-
bronchodilator; severe dyspnoea defined as score of 3–5
by MRC scale; #Po0.01 for gender distribution, *Po0.01
after adjustment for gender distribution and age.
M.A.P. Vermeeren et al.135273% of the COPD population had normal BMI and
normal FFMI, 15% normal BMI and low FFMI, 1% low
BMI and normal FFMI and 11% low BMI and low FFMI.
No differences in the prevalence of nutritional
depletion between GOLD stages 2 and 3 were
observed. The prevalence of the different nutri-
tional depletion combinations in male and female
COPD patients is presented in Fig. 1. Depletion of
body weight was significantly more present in
female (18%) than in male (10%) COPD patients,
Po0:01. The prevalence of FFM depletion was
significantly higher in female COPD patients (40%)
than in males (20%), Po0:001. In 25% of the female
COPD patients FFM depletion with body weight
preservation occurred, which was significantly
higher than in males (11%), Po0:05.Factors related to nutritional depletion
FEV1%pred and age were similar in depleted COPD
patients relative to non-depleted COPD patients.
Gender distribution was significantly different
between depleted and non-depleted COPD patients
(Po0:01). Therefore adjustment for gender dis-
tribution was applied in further analyses. Patients
suffering from depletion were characterized by asignificantly lower handgrip strength compared to
non-depleted patients, as shown in Table 2.
Dyspnoea score and health status did not signifi-
cantly differ between depleted and non-depleted
COPD patients.
Factors related to handgrip strength
Mean handgrip strength significantly correlated
with FFMI, r ¼ 0:22, Po0:001 (Fig. 2). Stepwise
regression analyses showed that gender, age and
FFM index independently explained 51% of the
variation in handgrip strength in the total patient
group, while FMI and FEV1%pred were excluded
from the model (Table 3).Discussion
This study shows that the prevalence of nutritional
depletion in a large out-patient COPD population in
The Netherlands is high: in 27% of the COPD
patients, recruited with FEV1 between 30% and
70%pred, body mass and/or FFM was depleted.
Independent of disease severity, depletion of FFM
was significantly correlated with impaired periph-
eral muscle strength. In this study, the prevalence
of nutritional depletion in female patients with
moderate to severe COPD was more pronounced.
The prevalence of nutritional depletion in a
large out-patient COPD population by body compo-
sitional analysis has not been reported previously.
ARTICLE IN PRESS
Table 3 Stepwise regression analysis to assess
independent variables to explain the variation in
handgrip strength (kg).
Prediction
variables
Effect Cumulative
R2
P-value
Sex (m/f) 15.2 0.43 o0.001
Age (years) 0.35 0.48 o0.001
Fat-free mass
index (kg/m2)
0.8 0.51 o0.001
Fat-mass index
(kg/m2)
NS
FEV1
(%predicted)
NS
FFMI (kg/m2)
25201510
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Figure 2 The correlation between handgrip strength and
FFMI. r ¼ 0:22, Po0:001, open circles: females, closed
circles: males.
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prevalence of nutritional depletion was quite
similar (21%), but lower relative to the prevalence
found in the study of Schols et al. (45%).2 The latter
discrepancy can be due to more severe COPD being
present in the study of Schols et al. Remarkably,
the 15% prevalence of FFM depletion in combina-
tion with BM preservation in our study was higher
than in the study of Engelen (4%).1 This may be
explained by different inclusion criteria of the
studies. The COSMIC study population was selected
at least two exacerbations accompanied with
corticosteroid or antibiotic treatment in the pre-
vious 12 months. It can be hypothesized that
frequent treatment with systemic corticosteroid
may induce protein catabolism adversely affectingskeletal muscle function. In cross-sectional studies
no relationship was found between depletion of
FFM and systemic corticosteroid use,18,19 but
Bernard and coworkers showed that the ratio
muscle function and muscle mass tended to be
lower in COPD patients exposed to systemic
corticosteroids.20 Little is known about changes in
body composition due to exacerbations in COPD
patients. There are two studies reporting body
composition during hospitalization for an acute
exacerbation in COPD patients21,22 and it seems
that FFM depletion with preservation of BM occurs
frequently in hospitalized COPD patients.21,22 An
acute exacerbation has been shown to be accom-
panied with higher levels of inflammatory media-
tors22,23 and different reports suggested a
relationship between the presence of depletion
and increased systemic inflammatory status.24,25
The observed higher prevalence of nutritional
depletion in our study might thus possibly be
explained by the higher exacerbation rate accom-
panied with an impaired chronic inflammatory
response and altered body composition. Otherwise,
the exacerbation rate in our population is not
exceptional high, since a comparable exacerbation
rate of 2.4 per patient per year has been previously
reported in a cohort of 101 COPD patients with
mean7SD FEV1 of 42719%pred.
26 Still we cannot
fully mile out that the inclusion criterion is a
confounder of the reported prevalence in the
current study.
Nutritional depletion has been shown to be
associated with adverse effects on respiratory and
peripheral muscle function, on exercise capacity
and on health status.1,2,4,27–30 In the current study
the association between nutritional depletion and
peripheral muscle strength was confirmed and
appeared to be independent of disease severity.
Besides FFM depletion, age and especially gender
were found to be independent predictors of muscle
weakness in COPD. Further, in contrast to the
studies concerning impaired health status in de-
pleted COPD patients,4,30 we found no significant or
clinically relevant differences in any score of SGRQ
nor in the dyspnoea score between depleted and
non-depleted COPD patients. The former could be
explained by the less impaired airflow limitation in
the majority of our study population. A recent
study in COPD showed that the threshold for
worsening of health status lies at FEV1o50%pred.31
Till now, COPD is predominantly considered as a
‘‘male’’ disease, but the prevalence of COPD will
become even higher in females than in men,
predominantly due to the changed smoking beha-
viour.32–34 Given this increased prevalence of COPD
in females, it is worthwhile considering possible
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proposed by other authors.35,36 An increased risk of
hospitalization has been reported previously in
female COPD patients.37 We found in our study that
FFM depletion occurred more frequently in female
than in male COPD patients. Gender differences in
body composition have been found in earlier
studies.1,2 Engelen and coworkers also reported a
higher prevalence of nutritional depletion in women
(35%) than in men (16%)1 and values in the study of
Schols et al. printing in the same direction, i.e. 42%
and 34%, respectively.2 A higher nutritional deple-
tion in females could also exist if females had more
severe COPD. However, in our study the female
COPD patients had even a better mean FEV1%pred
(54713%pred) compared to males (49712%pred).
Recently, several systemic effects in patients with
COPD have been described.38 Nutritional depletion
has been associated with lower diffusing capacity39
and with systemic inflammation in COPD pa-
tients.39–41 Therefore female COPD patients in our
study might have lower diffusing capacity or
increased inflammatory response, underlying the
observed gender difference. Further research is
required to unravel gender differences and its
consequences in patients with COPD.
The prevalence of FFM depletion in our study
(26%) is higher than in the other study, reporting
values of 18% in an out-patient COPD population.1
This discrepancy can be explained by differences in
disease severity, but also by differences in the used
formula to calculate FFM. We used a disease- and
gender-specific formula15 and in earlier reported
studies1,2 a disease-specific formula was used.42 In
comparison with reference values of FFMI in
healthy female subjects43 the FFMI cut-off point
in female COPD patients might be high,15 vs.
14.6 kg FFM/m2 (10th percentile of healthy female
subjects).43 However, using the FFMI cut-off point
of healthy female subjects (14.6 kg FFM/m2),43 the
prevalence of FFM depletion in our study popula-
tion remains high, namely 30%.
In conclusion, the prevalence of nutritional
depletion in our COPD population is high, and
especially so in female COPD patients. The pre-
sence of nutritional depletion was not associated
with lower levels of FEV1%pred. Peripheral muscle
weakness was associated with nutritional depletion
and gender and age were also found as independent
predictors of muscle weakness. Assessment of body
composition additional to body weight is therefore
necessary in all patients with COPD, independent of
the stage of disease severity. Since depletion of
FFM is an important determinant of functional
capacity in COPD patients, (early) detection is
essential in clinical practice.Acknowledgments
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